Neutrophil gelatinase-associated lipocalin, cystatin C and eGFR indicate acute kidney injury and predict prognosis of patients with acute pulmonary embolism

Abstract

Acute kidney injury assessed by N-GAL occurs in 30% of APE and may contribute to the impairment of renal function present in half of them. Moreover, N-GAL, cystatin C elevation and low eGFR are associated with a poor 30-day prognosis in APE.

Prognostic Value of Renal Dysfunction Indicators in Normotensive Patients With Acute Pulmonary Embolism

“…14-16 Similar observations were also made in studies investigating the relationship between APE and GFR. [6][7][8] These studies suggest a significant correlation between GFR and various radiological and echocardiographic right ventricular functional parameters, since eGFR MDRD is significantly correlated with the RV-LV ratio, PAOI, and SVC diameter. These findings support the hypothesis that this may be a predominant mechanism.…”

Pulmonary embolism: clinical guidelines of European Society of Cardiology (2014).The Task Force of the European Society of Cardiology for diagnosis and management of pulmonary embolism

“…Повышение концентрации нейтрофильного желати назо ассоциированного липокаина (NGAL) и циста тина С означает острую почечную недостаточность и имеет прогностическое значение [248]. В неко торых исследованиях повышение D димера сопро вождалось увеличением краткосрочной летально сти [249,250], тогда как концентрация D димера < 1 500 нг / мл имела отрицательное прогностичес кое значение 99 % для исключения общей 3 месяч ной летальности [251].…”

Renal biomarkers and prognosis in acute pulmonary embolism

“…Kostrubiec and co-workers6 investigated markers of acute kidney injury such as cystatin C and serum neutrophil gelatinase-associated lipocalin (N-GAL) and their association with left and right heart function, disease severity, and prognosis in patients with APE. Cystatin C is a 13 kDa endogenous cysteine proteinase inhibitor and is produced by nucleated cells at a constant rate.…”

“…The study of Kostrubiec and colleagues6 is promising, but it is too early to answer the question. Larger multicentre studies need to follow, and markers of acute kidney injury have to be validated against other biomarkers such as brain-type natriuretic peptide or troponin, which are already accepted components in risk stratifications models of patients with APE 14…”